IXARIS
Ixaris is a payment optimization company with an extensive portfolio of Mastercard® and Visa virtual cards, helping companies make smarter payment choices. Ixaris optimizes £billions in outbound payments for sectors including travel, media, and insurance. From launching Europe's first virtual cards to shaping the future of airline payments, innovation is in Ixaris' DNA. Ixaris group companies are based in London, Brussels, and Malta.
IXARIS
Industry:
Finance Financial Services FinTech Payments Productivity Tools
Founded:
2002-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.ixaris.com
Total Employee:
51+
Status:
Active
Contact:
44 20 3086 8042
Total Funding:
8.8 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS Cloudflare Hosting Apple Mobile Web App Capable Cloudflare SSL
Similar Organizations
Braintree
Braintree's payment platform provides all the tools online and mobile businesses need to accept payments.
Faster Payments Scheme
Faster Payments Scheme is the company that enables mobile, internet, telephone and standing order payments to move quickly.
Ingo Money
Ingo Money is a disbursement marketplace that digitizes the paper check.
Kantox
Kantox is a leader in Currency Management Automation software that enables businesses to automate their end-to-end FX workflow
Token
Token is an open banking payments platform driving the shift from traditional payment methods to bank payments.
Verse
Verse offers a payments platform that allows users to share payments easily, instantly, and with no hidden fees.
Current Advisors List
Board_member
2021-06-01
Board_member
2002-07-01
Current Employees Featured
Mark Anthony Spiteri CEO @ Ixaris
CEO
2004-01-01
Martin Peck Acting CFO @ Ixaris
Acting CFO
Reuben Abela CX Director @ Ixaris
CX Director
Andrew Calafato Technology Director @ Ixaris
Technology Director
Graziella Ellul Head of Product @ Ixaris
Head of Product
Founder
Investors List
Future Fifty
Future Fifty investment in Non Equity Assistance - Ixaris
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Ixaris
Foresight Group
Foresight Group investment in Private Equity Round - Ixaris
Oxford Technology Management
Oxford Technology Management investment in Seed Round - Ixaris
Newest Events participated
Participated in Money20/20 Europe 2017
on 2017-06-26 as sponsor
Participated in Innovate Finance Global Summit 2017
on 2017-04-10 as exhibitor
Participated in Innovate Finance Global Summit 2017
on 2017-04-10 as sponsor
Official Site Inspections
http://www.ixaris.com Semrush global rank: 91.73 K Semrush visits lastest month: 1.11 M
- Host name: 91.216.153.40
- IP address: 91.216.153.40
- Location: Malta
- Latitude: 35.8333
- Longitude: 14.5833
- Timezone: Europe/Malta
More informations about "Ixaris"
Ixaris - Crunchbase Company Profile & Funding
Ixaris is a payment optimization company with an extensive portfolio of Mastercard® and Visa virtual cards, helping companies make smarter payment choices.See details»
Autoinflammatory Disease Treatment | ILARIS® (canakinumab)
The most common side effects of ILARIS when used for the treatment of Still's disease (AOSD and SJIA) include: cold symptoms, upper respiratory tract infection, pneumonia, runny nose, …See details»
Ixaris - Company Profile - Tracxn
Dec 1, 2024 Ixaris - Open payment solutions provider.. Acquired by NIUM. Raised a total funding of $6M over 2 rounds from 2 investors. Founded by Alex Mifsud in the year 2002. Ixaris has 7 …See details»
Ixaris Systems Company Profile | Management and Employees List
Ixaris Systems Profile and History. Ixaris is a payments optimisation company with an extensive portfolio of virtual Mastercard and Visa cards that helps companies make smarter payment …See details»
Ixaris - LinkedIn
Ixaris | 5,850 followers on LinkedIn. Fintech innovator shaking up payments for the travel industry — and beyond. | An award-winning payments optimisation platform that helps companies …See details»
Ixaris Company Profile 2024: Valuation, Investors, Acquisition
Information on acquisition, funding, cap tables, investors, and executives for Ixaris. Use the PitchBook Platform to explore the full profile.See details»
Ixaris - VentureRadar
"Ixaris makes complex global payments easy, fast and accessible. Our groundbreaking technology enables global funds transfers through the Visa, MasterCard and SWIFT networks, …See details»
Ixaris - Contacts, Employees, Board Members, Advisors & Alumni
Edit Board Member and Advisor Profiles Section. Number of Board Member and Advisor Profiles 2. Ixaris has 2 board members and advisors, including David Nilsson.See details»
ILARIS® (canakinumab) | Health Care Professional Site
ILARIS has not been studied in patients with a positive TB screen, and the safety of ILARIS in individuals with latent TB infection is unknown. Treat patients testing positive in TB screening …See details»
Co-Pay Assistance | ILARIS® (canakinumab)
ILARIS Companion is a patient support program with multiple resources to help you every step of your ILARIS ® treatment journey. Read below for details on getting your ILARIS as prescribed, …See details»
Ilaris® | Novartis
Patient Organization Funding Patients perspectives stories Patients and Caregivers. Information for patients and their caregivers including clinical trial recruiting, managed access programs, …See details»
Ilaris® receives Health Canada approval as first of its ... - Newswire
Apr 29, 2021 Ilaris is a genetically engineered high-affinity human anti-human-interleukin-1 beta (IL-1β) monoclonal antibody, administered by subcutaneous injection every four weeks in the …See details»
Canakinumab - Wikipedia
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout …See details»
Novartis Pharmaceuticals Canada Inc. receives Health Canada
Dec 17, 2013 About ILARIS* ILARIS * is a selective, fully human, monoclonal antibody that inhibits IL-1 beta, which is an important part of the body's immune system defenses [1]. …See details»
LARIS I COMPANION - ilarishcp.com
ILARIS Companion representative at 1-866-972-8315 . IMPORTANT SAFETY INFORMATION (cont) WARNINGS AND PRECAUTIONS (cont) Serious Infections (cont) Prior to initiating …See details»
LARIS I COMPANION - ilarishcp.com
Prior to initiating immunomodulatory therapies, including ILARIS®, patients should be evaluated for active and latent TB infection. Appropriate screening tests should be performed in all …See details»
ILARIS Companion | ILARIS® (canakinumab) - HCP
In addition, because ILARIS may interfere with normal immune response to new antigens, vaccinations may not be effective in patients receiving ILARIS. Canakinumab, like other …See details»
Dosing Information for CAPS | ILARIS® (canakinumab)
ILARIS targets an important cause of CAPS symptoms For children and adults with CAPS, the immune system (the body's natural defense system that protects against "foreign" invaders) produces too much of or is too sensitive to a substance called a cytokine Too much of a cytokine called interleukin-1 beta (IL-1β) is an important cause of inflammation in CAPS.See details»
CAPS Treatment Support | ILARIS® (canakinumab)
The most common side effects of ILARIS when used for the treatment of CAPS include: cold symptoms, diarrhea, flu (influenza), runny nose, headache, cough, body aches, nausea, …See details»
Ilaris: 7 things you should know - Drugs.com
Sep 24, 2023 Ilaris (canakinumab) is an injected biologic medicine known as a monoclonal antibody that blocks certain proteins in the body. It is injected subcutaneously (under the skin) …See details»